Check Cap (NASDAQ:CHEK) issued its earnings results on Thursday, March 28th. The medical research company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.04), MarketWatch Earnings reports.
Check Cap stock traded up $0.09 during midday trading on Friday, hitting $2.55. 52,629 shares of the stock were exchanged. Check Cap has a 1 year low of $1.62 and a 1 year high of $19.78.
A number of equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Check Cap from a “buy” rating to a “hold” rating in a research note on Tuesday, April 9th. Dougherty & Co assumed coverage on shares of Check Cap in a research note on Tuesday, February 5th. They set a “buy” rating and a $6.00 price target on the stock.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Recommended Story: Different Types of Derivatives
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.